| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000024485 |
| Receipt No. | R000028047 |
| Official scientific title of the study | Preliminary study of clinical performance of simultaneous quantification assay for cytomegalovirus DNA, Epstein-Barr DNA, and human herpesvirus 6 DNA |
| Date of disclosure of the study information | 2016/10/31 |
| Last modified on | 2018/03/07 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | Preliminary study of clinical performance of simultaneous quantification assay for cytomegalovirus DNA, Epstein-Barr DNA, and human herpesvirus 6 DNA | |
| Title of the study (Brief title) | Clinical performance of quantification assay for CMV, EBV, and HHV6 DNA | |
| Region |
|
|
| Condition | |||
| Condition | Stem cell transplantation | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To study clinical performance of a newly developed assay kit for quantifying CMV, EBV, HHV6 DNA |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | This kit will be used for quantifying CMV, EBV, HHV6 DNA in peripheral blood of transplanted patients in order to evaluate clinical performance of the kit in comparison with a home brew kit of Nagoya University and calculating correlation coefficient. |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) recipients of stem cell transplantation
2) recipients and/or their parents or legal guardians who are willing and able to give signed consent |
|||
| Key exclusion criteria | recipients whom the investigator deemed ineligible to this study | |||
| Target sample size | 30 | |||
| Research contact person | |
| Name of lead principal investigator | Hiroshi Kimura |
| Organization | Nagoya University Graduate School of Medicine |
| Division name | Department of Virology |
| Address | 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550 |
| TEL | 052-744-2450 |
| hkimura@med.nagoya-u.ac.jp | |
| Public contact | |
| Name of contact person | Hiroshi Kimura |
| Organization | Nagoya University Graduate School of Medicine |
| Division name | Department of Virology |
| Address | 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550 |
| TEL | 052-744-2450 |
| Homepage URL | |
| multiplex@med.nagoya-u.ac.jp | |
| Sponsor | |
| Institute | Nagoya University Graduate School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Japan Agency for Medical Research and Development |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 名古屋大学医学部附属病院(愛知県)
藤田保健衛生大学医学部附属病院(愛知県) 名古屋第一赤十字病院(愛知県) 国家公務員共済組合連合会 虎の門病院(東京都) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | To evaluate the presence of each viral infection, following information is scheduled to be collected from medical records.
1) Sex/ Age 2) Transplantation information 3) Complications 4) Pathological findings 5) Imaging finding 6) Therapies against viral infections 7) Laboratory tests 8) CMV pp65 9) Flow cytometry 10) Clinical findings related with each viral infection |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028047 |